natgillin/translations-raw huggingface dataset:
Interaction with other veterinary medicinal products and other forms of interaction
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Interaction with other veterinary medicinal products and other forms of interaction Intravenous Anaesthetics:
Medsebojno delovanje z drugimi veterinarskimi zdravili in druge oblike interakcij Anestetiki za intravensko uporabo:
Interaction with ritonavir: The recommended dose of Invirase and ritonavir is 1000 mg Invirase plus 100 mg ritonavir twice daily.
Medsebojno delovanje z ritonavirjem: priporočeni odmerek zdravila Invirase in ritonavirja je 1000 mg zdravila Invirase in 100 mg ritonavirja dvakrat na dan.
Interaction with tipranavir: Concomitant use of boosted saquinavir and tipranavir, co-administered with low dose ritonavir in a dual-boosted regimen, results in a significant decrease in saquinavir plasma concentrations (see section 4.5).
Medsebojno delovanje s tipranavirjem: pri sočasni uporabi sakvinavirja in tipranavirja, danima sočasno s podporno terapijo nizkih odmerkov ritonavirja v režimu dvojne podporne terapije, je prišlo do značilnega zmanjšanja koncentracij sakvinavirja v plazmi (glejte poglavje 4.5).
Interaction with warfarin and vitamin K antagonists leading to an increased INR
Medsebojno delovanje z varfarinom in antagonisti vitamina K, ki lahko pripeljejo do povišane vrednosti INR.
Interaction – Change in Everolimus AUC/Cmax Geometric mean ratio (observed range)
Interakcija – sprememba razmerja AUC/Cmax everolimusa razmerje geometričnih sredin (obseg dejanskih razmerij)
Interaction:
Interakcije:
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS
MEDSEBOJNA DELOVANJA Z DRUGIMI ZDRAVILI IN PRIPOROČILA ZA ODMERJANJE
Interactions between Atripla or its individual component(s) and other medicinal products are listed in Table 1 below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, twice daily as “b.i.d.”, once daily as “q.d.” and once every 8 hours as “q8h”).
Interakcije med zdravilom Atripla ali posameznimi učinkovinami zdravila in drugimi zdravili so navedene v tabeli 1 spodaj (povečanje je označeno z znakom „↑“, zmanjšanje z „↓“, brez spremembe z „↔“).
Interactions between darunavir/ritonavir and antiretroviral and non-antiretroviral medicinal products are listed in the table below (not determined as “ND”).
Interakcije med darunavirjem/ritonavirjem in drugimi protiretrovirusnimi in ne-protiretrovirusnimi zdravili so navedene v spodnji preglednici (ni podatka je prikazano z “ND”).
Interactions between dolutegravir and co-administered medicinal products are listed in Table 1 (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, area under the concentration versus time curve as “AUC”, maximum observed concentration as “Cmax”, concentration at end of dosing interval as “Cτ”).
Interakcije med dolutegravirjem in sočasno uporabljenimi zdravili so navedene v preglednici 1 (zvečanje je označeno kot “↑”, zmanjšanje kot “↓”, brez spremembe kot “↔”, površina pod koncentracijsko krivuljo v odvisnosti od časa kot “AUC”, maksimalna zabeležena koncentracija kot “Cmax”, koncentracija na koncu odmernega intervala pa kot “Cτ”).
Interactions between efavirenz and protease inhibitors, antiretroviral agents other than protease inhibitors and other non-antiretroviral medicinal products are listed in Table 1 below (increase is indicated as “j”, decrease as “0”, no change as “+--”, and once every 8 or 12 hours as “q8h” or “q12h”).
Interakcije med efavirenzem in zaviralci proteaze, protiretrovirusnimi učinkovinami, ki niso zaviralci proteaze, in drugimi neprotiretrovirusnimi zdravili so navedene v preglednici 3 spodaj (povečanje je označeno z znakom "↑", zmanjšanje z "↓", brez spremembe z "↔", ter enkrat na 8 ur oz.
Interactions between efavirenz and protease inhibitors, antiretroviral agents other than protease inhibitors and other non-antiretroviral medicinal products are listed in Table 1 below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, and once every 8 or 12 hours as “q8h” or “q12h”).
Interakcije med efavirenzem in zaviralci proteaze, protiretrovirusnimi učinkovinami, ki niso zaviralci proteaze, in drugimi neprotiretrovirusnimi zdravili so navedene v preglednici 1 spodaj (povečanje je označeno z znakom “↑”, zmanjšanje z “↓”, brez spremembe z “↔”, ter enkrat na 8 ur oz.
Interactions between efavirenz and protease inhibitors, antiretroviral agents other than protease inhibitors and other non-antiretroviral medicinal products are listed in Table 2 below (increase is indicated as “j”, decrease as “0”, no change as “+--”, and once every 8 or 12 hours as “q8h” or “q12h”).
Interakcije med efavirenzem in zaviralci proteaze, protiretrovirusnimi učinkovinami, ki niso zaviralci proteaze, in drugimi neprotiretrovirusnimi zdravili so navedene v preglednici 1 spodaj (povečanje je označeno z znakom "↑", zmanjšanje z "↓", brez spremembe z "↔", ter enkrat na 8 ur oz.
Interactions between efavirenz and protease inhibitors, antiretroviral agents other than protease inhibitors and other non-antiretroviral medicinal products are listed in Table 2 below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, and once every 8 or 12 hours as “q8h” or “q12h”).
Interakcije med efavirenzem in zaviralci proteaze, protiretrovirusnimi učinkovinami, ki niso zaviralci proteaze, in drugimi neprotiretrovirusnimi zdravili so navedene v preglednici 2 spodaj (povečanje je označeno z znakom "↑", zmanjšanje z "↓", brez spremembe z "↔", ter enkrat na 8 ur oz.
Interactions between Epclusa and other medicinal products
Interakcije med zdravilom Epclusa in drugimi zdravili
Interactions between Ilaris and other medicinal products have not been investigated in formal studies.
Medsebojnega delovanja zdravila Ilaris in drugih zdravil niso raziskovali s formalnimi študijami.
Interactions between indinavir and other medicinal products are listed in the tables below (increase is indicated as “↑”, decrease as “↓”, no change (≤ +/- 20 %) as “↔”, single dose as “SD”, once daily as “QD”, twice daily as “BID”, three times daily as “TID”, and four times daily as "QID").
Medsebojno delovanje indinavirja in drugih zdravil je navedeno v spodnjih tabelah (povečanje je označeno kot "↑", zmanjšanje kot "↓", brez spremembe (≤ +/– 20 %) kot "↔", enkratni odmerek kot "SD", enkrat na dan kot "QD", dvakrat na dan kot "BID", trikrat na dan kot "TID" in štirikrat na dan kot "QID").
Interactions between indinavir/ritonavir and other medicinal products are listed in the tables below (increase is indicated as “↑”, decrease as “↓”, no change (≤ +/- 20 %) as “↔”, single dose as “SD”, once daily as “QD”, twice daily as “BID”, three times daily as “TID”, and four times daily as "QID").
Medsebojno delovanje indinavirja/ritonavirja in drugih zdravil je navedeno v spodnjih tabelah (povečanje je označeno kot "↑", zmanjšanje kot "↓", brez spremembe (≤ +/– 20 %) kot "↔", enkratni odmerek kot "SD", enkrat na dan kot "QD", dvakrat na dan kot "BID", trikrat na dan kot "TID" in štirikrat na dan kot "QID").
Interactions between Kaletra and co-administered medicinal products are listed in the table below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”,once daily as “QD”, twice daily as “BID” and three times daily as "TID").
V spodnji preglednici so navedena medsebojna delovanja med zdravilom Kaletra in sočasno uporabljenimi zdravili (zvišanje je označeno z "↑", znižanje z "↓" in ni spremembe z "↔".
Interactions between PREZISTA /ritonavir and antiretroviral and non-antiretroviral medicinal products are listed in the table below (not determined as “ND”).
Interakcije med zdraviloma PREZISTA/ritonavirj in drugimi protiretrovirusnimi in ne-protiretrovirusnimi zdravili so navedene v spodnji preglednici (ni podatka je prikazano z “ND”).
Interactions between PREZISTA/ritonavir and antiretroviral and non-antiretroviral medicinal products are listed in the table below (not determined as “ND”).
Interakcije med zdraviloma PREZISTA/ritonavirj in drugimi protiretrovirusnimi in ne-protiretrovirusnimi zdravili so navedene v spodnji preglednici (ni podatka je prikazano z “ND”).
Interactions between tenofovir disoproxil fumarate and other medicinal products are listed in Table 1 below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, twice daily as “b.i.d.”, and once daily as “q.d.”).
Interakcije med dizoproksiltenofovirijevim fumaratom in drugimi zdravili so navedene v preglednici 1 spodaj (povečanje je označeno z znakom “↑”, zmanjšanje z “↓”, brez spremembe z “↔”, dvakrat na dan z “bid.”, enkrat na dan pa s “q.d.”).
Interactions between tenofovir disoproxil fumarate and other medicinal products are listed in Table 2 below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, twice daily as “b.i.d.”, and once daily as “q.d.”).
Interakcije med dizoproksiltenofovirijevim fumaratom in drugimi zdravili so navedene v preglednici 2 spodaj (povečanje je označeno z znakom “↑”, zmanjšanje z “↓”, brez spremembe z “↔”, dvakrat na dan z “bid.”, enkrat na dan pa s “q.d.”).
Interactions between the components of DUTREBIS and co-administered medicinal products are listed in Table 1 below.
Medsebojno delovanje med učinkovinama zdravila DUTREBIS in sočasno uporabljenimi zdravili so prikazane spodaj v preglednici 1.
Interactions between Truvada or its individual component(s) and other medicinal products are listed in Table 2 below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, twice daily as “b.i.d.” and once daily as “q.d.”).
Interakcije med zdravilom Truvada ali njegovo(-imi) posamično(-imi) učinkovino(-ami) in drugimi zdravili so navedene v preglednici 2 spodaj (povečanje je označeno z znakom “↑”, zmanjšanje z “↓”, brez spremembe z “↔”, dvakrat na dan z “b.i.d.” in enkrat na dan pa s “q.d.”).
Interactions common to all cytotoxics
Medsebojna delovanja, ki so skupna vsem citostatikom
Interactions common to all cytotoxics:
Medsebojna delovanja, ki so skupna vsem citotoksičnim zdravilom
Interactions common to the combination
Pogoste interakcije kombinacije
Interactions linked to amlodipine Concomitant use not recommended Grapefruit or grapefruit juice
Interakcije, povezane z amlodipinom Sočasna uporaba ni priporočena Grenivka ali grenivkin sok
Interactions linked to amlodipine Concomitant use not recommended Grapefruit or grapefruit juice
Interakcije, povezane z amlodipinom Sočasna uporaba ni priporočljiva Grenivka ali grenivkin sok
Interactions linked to dabigatran etexilate and dabigatran metabolic profile
Interakcije, povezane z dabigatran eteksilatom in presnovnimi lastnostmi dabigatrana
Interactions linked to dabigatran etexilate and dabigatran metabolic profile
Interakcije, povezane z dabigatran eteksilatom in presnovnimi lastnostmi dabigatrana:
Interactions linked to valsartan Concomitant use not recommended Lithium
Interakcije, povezane z valsartanom Sočasna uporaba ni priporočljiva Litij
Interactions mediated by effects on transporters
Interakcije, pri katerih posredujejo učinki na prenašalce
Interactions of cobicistat and potential co-administered medicinal products are listed in Table 2 below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”).
Interakcije med kobicistatom in možnimi sočasno uporabljenimi zdravili so navedene v preglednici 2 spodaj (zvišanje je označeno z znakom "↑", zmanjšanje z "↓", brez spremembe z "↔").
Interactions relevant to monotherapies
Interakcije, ki se nanašajo na posamezni učinkovini
Interactions relevant to pravastatin
Interakcije, pomembne za pravastatin
Interactions requiring caution
Medsebojna delovanja, ki zahtevajo previdnost
Interactions requiring dose adjustment of Vitekta
Interakcije, zaradi katerih je treba prilagoditi odmerek zdravila Vitekta
Interactions resulting in concomitant use not being recommended
Interakcije, zaradi katerih sočasna uporaba ni priporočena
Interactions with doxorubicin have also been reported for streptozocin, phenobarbital, phenytoin and warfarin.
O medsebojnem delovanju z doksorubicinom so poročali tudi pri streptozocinu, fenobarbitalu, fenitoinu in varfarinu.
Interactions with drug uptake transport systems
Medsebojno delovanje s transportnimi sistemi za privzem zdravil
Interactions with other antibacterial agents
Interakcije z drugimi protibakterijskimi zdravili
Interactions with other drug types have not been specifically investigated.
Ni podatkov o medsebojnem delovanju z drugimi vrstami zdravil.
Interactions with other medicinal products
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Interactions with other medicinal products and other forms of interaction:
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Interactions with other medicinal products and other forms of interactions
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Interactions with potassium-sparing diuretics such as spironolactone, triamterene or amiloride cannot be ruled out.
Medsebojnega delovanja z diuretiki, ki zadržujejo kalij, kot so spironolakton, triamteren ali amilorid, ni mogoče izključiti.
Interactions with strong CYP3A4 inducers
Interakcije z močnimi induktorji encima CYP3A4
Interactions with strong CYP3A4 inhibitors or strong UGT1A1 inhibitors
Interakcije z močnimi zaviralci encima CYP3A4 ali močnimi zaviralci encima UGT1A1
Interactions with systemic drugs would be limited by the minimal percutaneous absorption of imiquimod cream.
Interakcije s sistemskimi zdravili bi bile omejene zaradi minimalne absorpcije imikvimod kreme skozi kožo.
Interactions with transport proteins
Medsebojno delovanje s prenašalnimi beljakovinami
Intercurrent events, in particular dehydratation, acute cardiac decompensation, metabolic acidosis, worsening of renal function, sudden worsening of the renal condition (e.g. infectious diseases), cellular lysis (e.g. acute limb ischemia, rhabdomyolysis, extend trauma).
vključno s selektivnimi zaviralci CO-2), heparin, imunosupresivi (ciklosporin ali takrolimus) in trimetoprim. sočasne bolezni, zlasti dehidracija, akutno srčno popuščanje, metabolična acidoza, slabše delovanje ledvic, nenadno poslabšanje stanja ledvic (npr. infekcijske bolezni), liza celic (npr. akutna ishemija uda, rabdomioliza, obširna travma).
intercurrent illness (e.g. vomiting, diarrhoea),
očasna bolezen (npr. bruhanje, driska),
Intercurrent Respiratory Illness
Interkurentne bolezni dihal
Interference may occur in the vicinity of equipment marked with the following symbol:
V bližini opreme s tem simbolom lahko pride do motnje:
Interference with certain coagulation assays has been detected in patients treated with Cimzia.
Pri bolnikih, ki so se zdravili z zdravilom Cimzia, so opazili interferenco z nekaterimi testi koagulacije.
Interference with determination of Complete Response
Vpliv na določanje popolnega odgovora na zdravljenje
Interference with laboratory testing
Moteč vpliv na laboratorijske preiskave
Interference with Magnetic Resonance Imaging (MRI)
Vpliv na magnetnoresonančno slikanje (MRI- Magnetic Resonance Imaging)
Interference with mitochondrial electron transport
motnjami prenosa elektronov v mitohondriju,
Interference with serum or urinary testing
Vpliv na rezultate testiranja v serumu ali urinu
Interference with Serum Protein Electrophoresis and Immunofixation Tests
Vpliv na elektroforezo serumskih proteinov in imunofiksacijo
Interferon alfa-2a is conjugated with bis-[monomethoxy polyethylene glycol] at a degree of substitution of one mole of polymer/mole of protein.
Interferon alfa-2a je konjugiran z molekulo bis-monometoksipolietilenglikol pri stopnji substitucije en mol polimera na mol proteina.
Interferon alfa-2b has been shown to be an abortifacient in primates.
Pokazali so, da ima interferon alfa-2b pri primatih abortivni učinek.
interferon alpha ,
interferona alfa,
interferon alpha,
interferona alfa,
interferon alpha/ribavirin
40,2; 58,8
Interferon beta 1-a is a form of a protein that is naturally produced by the body.
Interferon beta 1-a je vrsta beljakovine, ki jo telo naravno proizvaja.
Interferon beta-1a is mainly metabolised and excreted by the liver and the kidneys.
Interferon beta-1a se v glavnem presnavlja in izloča skozi jetra in ledvice.
Interferon beta-1a is produced by a method known as ‘recombinant DNA technology’: it is made by cells into which a gene (DNA) has been introduced, which makes them able to produce interferon beta-1a.
Interferon beta-1a proizvajajo z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri je bil v celice vstavljen gen (DNK), s katerim lahko tvorijo interferon beta-1a.
Interferon beta-1a is produced by a method known as ‘recombinant DNA technology’: the interferon beta-1a is made by a cell that has received a gene (DNA), which makes it able to produce it.
Interferon beta-1a proizvajajo z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri celica prejme gen (DNK), s katerim lahko tvori interferon beta-1a.
Interferon beta-1a SC use
interferon beta-1a s.c. uporaba
Interferon beta-1b has been given to adult cancer patients at individual doses as high as
Interferon beta-1b so dajali odraslim bolnikom z rakom v individualnih odmerkih do
Interferon classification
Razvrstitev glede na interferon
Interferon may impair fertility (see section 4.6 and section 5.3).
Interferon lahko zmanjša plodnost (glejte poglavji 4.6 in 5.3).
Interferon medicine that is used in combination with this medicine may cause unusual tiredness; if you are injecting this medicine yourself or giving it to a child, use it at bedtime.
Interferoni, ki se uporabljajo v kombinaciji s tem zdravilom, lahko povzročijo neobičajno utrujenost; če si zdravilo injicirate sami ali če ga dajete otroku, ga dajte pred spanjem.
interferon, to treat viral infections
interferon za zdravljenje virusnih okužb,
interferon, to treat viral infections
interferon za zdravljenje virusnih okužb;
Interferons alpha and beta are classified as Type I interferons and interferon gamma is a Type II interferon.
Interferoni alfa in beta so klasificirani kot interferoni tipa I, interferon gama pa je interferon tipa II.
Interferons and Nevirapine Teva may be co-administered without dose adjustments.
Interferone in zdravilo Nevirapin Teva lahko dajemo sočasno, brez prilagajanja odmerkov.
Interferons are a family of naturally occurring proteins that are induced by cells in response to biological and chemical stimuli, and mediate numerous cellular responses that have been classified as antiviral, antiproliferative, and immunomodulatory in nature.
Interferoni so družina beljakovin, ki se v telesu pojavljajo normalno in jih celice inducirajo v odziv na biološke in kemične dražljaje, in prenašajo številne celične odzive, ki so bili razvrščeni med protivirusne, antiproliferativne in imunomodulacijske.
Interferons are a family of naturally occurring proteins that are induced by cells in response to biological and chemical stimuli, and mediate numerous cellular responses that have been classified as antiviral, antiproliferative, and immunomodulatory in nature.
Interferoni so družina beljakovin, ki se v telesu pojavljajo normalno in jih celice inducirajo v odziv na biološke in kemične dražljaje, in prenašajo številne celične odzive, ki so bili razvrščeni med protvirusne, antiproliferativne in imunomodulacijske.
Interferons are cytokines that mediate antiviral, antiproliferative and immunomodulatory activities.
Interferoni so citokini, ki posredujejo pri antivirusnih, antiproliferacijskih in imunomodulacijskih aktivnostih.
Interferons are cytokines that mediate antiviral, antiproliferative, and immunomodulatory activities.
Interferoni so citokini, ki posredujejo pri antivirusnih, antiproliferacijskih in imunomodulacijskih aktivnostih.
Interferons are made by your body’s immune system to help fight infections and severe diseases.
Interferone izdeluje vaš telesni imunski sistem za pomoč pri premagovanju okužb in hudih bolezni.
Interferons are natural substances produced by the body that help it fight infections caused by viruses.
To so naravne snovi, ki jih telo proizvaja za obrambo pred okužbami, ki jih povzročajo virusi.
interferons taken with or without ribavirin – used to treat hepatitis.
interferone (z ribavirinom ali brez njega) – uporabljajo se za zdravljenje hepatitisa
Interim
Vmesni
Interim analyses reports provided annually beginning Q4 2015 until completion of the study program.
Letna predložitev vmesnih poročil od začetka 4. četrtletja 2015 vse do zaključka programa študij.
Interim analysis of results (as of May 2015) from the ongoing TYSABRI Observational Program (TOP), a phase 4, multicentre, single-arm study (n=5770) demonstrated that patients switching from beta interferon (n= 3255) or glatiramer acetate (n= 1384) to TYSABRI showed a sustained, significant decrease in annualised relapse rate (p< 0.0001).
Vmesna analiza rezultatov (maja 2015) potekajočega opazovalnega programa zdravila TYSABRI (TOP-TYSABRI Observational Program), multicentrične študije 4. faze z enim krakom (n = 5770), je pokazala, da so bolniki, ki so prešli z interferona beta (n = 3255) ali glatiramer acetata (n = 1384) na zdravilo TYSABRI, pokazali dolgotrajno pomembno zmanjšanje letne stopnje recidivov (p< 0,0001).
Interim data from a phase 2 study in 9 HCV infected post-liver transplant patients.
Vmesna analiza podatkov iz študije faze 2 pri 9 bolnikih s presaditvijo jeter, okuženih s HCV.
Interim data from an ongoing study of cardiovascular outcomes were reviewed during the assessment although the CHMP also recommended ongoing monitoring of the medicine’s cardiovascular effects.
Med ocenjevanjem so bili pregledani vmesni podatki iz potekajoče študije o srčno-žilnih izidih, čeprav je odbor prav tako priporočil stalno spremljanje učinkov zdravila na srce in ožilje.
Interim IDMC analysis when half of the patients reach W76: 2Q 2018
Letne posodobitve napredka študije v okviru letnih vlog za podaljšanje dovoljenja za promet z zdravilom
Interim OS (52% maturity)
Vmesno celokupno preživetje (52 % zrelost)
Interim reports expected yearly within PSURs
Vmesna poročila se pričakujejo enkrat letno v okviru PSUR
Interim reports should be provided at the time of annual re- assessments.
Vmesna poročila je treba predložiti v času letnih ponovnih ocen.
Interim reports submitted yearly in the frame of the Annual Re-assessment
Letna predložitev vmesnih poročil v okviru vsakoletne ponovne ocene
Interim results showed an increased risk of mortality and serious adverse events in subjects receiving riociguat compared to those receiving placebo.
Vmesni rezultati so pokazali povečano tveganje za umrljivost in resne neželene učinke pri preiskovancih, ki so prejemali riociguat, v primerjavi s preiskovanci, ki so prejemali placebo.
Interim Study
Vmesna poročila o
Interim survival analysis
vmesna analiza preživetja
Interindividual variability in systemic clearance is about 15.
Interindividualna variabilnost sistemskega očistka je približno 15%.
Interindividual variability in the volume of distribution of parathyroid hormone is about 40.
Interindividualna variabilnost volumna porazdelitve obščitničnega hormona je približno 40%.
Interleukin-2 (IL-2): 3 MIU/m2/day administered by continuous intravenous infusion over 96 hours on Days 1-4 and4.5 MIU/m2/day on Days 8-11.
Interleukin-2 (IL-2): 3 M i.e./m2/dan, aplicirano prek neprekinjene intravenske infuzije v 96 urah od 1. do 4. dne in 4,5 M i.e./m2/dan od 8. do 11. dne.
Interleukin-2 (IL-2, aldesleukin)
Interlevkin-2 (IL-2; aldeslevkin)
interleukin-2 (to treat cancer)
interlevkin-2 (za zdravljenje raka)
interleukin-2 (to treat cancer) non-steroidal anti-inflammatory drugs (NSAIDs, to relieve bone or muscle pains)
interlevkin-2 (za zdravljenje raka). nesteroidna protivnetna zdravila (NSAID, za lajšanje bolečin v kosteh ali mišicah)
interleukin-2 (to treat cancer), adefovir dipivoxil (for HBV),
interlevkin-2 (za zdravljenje raka); dipivoksiladefovirat (za okužbo z virusom HBV);
interleukin-2 (to treat cancer).
interlevkin-2 (za zdravljenje raka).
interleukin-2, also called aldesleukin (to treat cancer) non-steroidal anti-inflammatory drugs (NSAIDs, to relieve bone or muscle pains)
interlevkin-2, imenovan tudi aldeslevkin (za zdravljenje raka) nesteroidna protivnetna zdravila (NSAID, za lajšanje bolečin v kosteh ali mišicah)